Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Excelsior Medical CoTPE:4104 -0.28%87 EBITDA Margin % is 16.06% as of Mar. 2026, which is 2% above its 10-year median of 15.80. GuruFocus rates TPE:4104 with a GF Score™ of 87/100 and a GF Value™ of NT$87.68 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 118 Medical Distribution companies, Excelsior Medical Co ranks better than 90.68% on this metric.
Excelsior Medical Co (TPE:4104) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Excelsior Medical Co EBITDA Margin % Related Terms
Excelsior Medical Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Excelsior Medical Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4104 vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Excelsior Medical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Excelsior Medical Co EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Excelsior Medical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Excelsior Medical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Excelsior Medical Co (TPE:4104) has a EBITDA Margin % of 16.06% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Excelsior Medical Co and its competitors. This is near median its historical median of 15.80. Over the past decade, Excelsior Medical Co's EBITDA Margin % has ranged from 11.01 to 17.59. According to the industry distribution chart, Excelsior Medical Co ranks #11 out of 118 companies in the Medical Distribution industry, placing it in the top 9.3%.
Is Excelsior Medical Co's EBITDA Margin % too high?
Excelsior Medical Co's current EBITDA Margin % of 16.06% is near median its 10-year median of 15.80. Over the past 10 years, this metric has ranged from a low of 11.01 to a high of 17.59. The Medical Distribution industry median EBITDA Margin % is 4.16. Excelsior Medical Co's value of 16.06% is 286.5% above this industry median. Based on the distribution chart, Excelsior Medical Co ranks #11 out of 118 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Excelsior Medical Co has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Excelsior Medical Co's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Excelsior Medical Co ranks #11 out of 118 companies for EBITDA Margin %. This places Excelsior Medical Co in the top 9% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 4.16. Excelsior Medical Co's value of 16.06% is 286.5% above this benchmark. Historically, Excelsior Medical Co's own EBITDA Margin % has ranged from 11.01 to 17.59 over the past decade. While the company's 10-year median is 15.80 vs. the industry median of 4.16, Excelsior Medical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.16, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Excelsior Medical Co's current EBITDA Margin % of 16.06% is 286.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Excelsior Medical Co and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Excelsior Medical Co's current EBITDA Margin % is 16.06%, which is near median its own 10-year median of 15.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Excelsior Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Excelsior Medical Co (TPE:4104) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.68, compared to a current price of NT$70.80 — trading 19.3% below its estimated fair value. The current EBITDA Margin % is 16.06%, which is near median its 10-year median of 15.80 and 286.5% above the Medical Distribution industry median of 4.16. Excelsior Medical Co's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Excelsior Medical Co (TPE:4104), the current EBITDA Margin % is 16.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Excelsior Medical Co (TPE:4104) Overvalued in 2026?
Based on GuruFocus' analysis, Excelsior Medical Co stock appears to be undervalued.
The current stock price of NT$70.80 is trading 19.3% below its estimated GF Value™ of NT$87.68.
GuruFocus considers Excelsior Medical Co to be Modestly Undervalued.
Key valuation signals for TPE:4104:
EBITDA Margin %: 16.06% (near median its 10-year median of 15.80)
GF Value™: NT$87.68 vs. price of NT$70.80 (19.3% below fair value)
Industry Position: 286.5% above the Medical Distribution median (#11 of 118)
No single metric tells the full story. See the TPE:4104 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Excelsior Medical Co Ltd is engaged in the sale of medical supplies and medicines, home medical devices, and medical equipment with brand names of local and foreign manufacturers. Its product offerings include Fasflo hollow fiber dialyzer, Renabio sodium chloride injection, acid concentrates, Sunder blood purification tubing set, JMS blood bags, etc. The Group's reportable segments include Excelsior, Dynamic, Arich, and Others. Maximum revenue is generated from the Excelsior segment. Geographically, it derives key revenue from Taiwan and also has a presence in Hong Kong, China, the Philippines, Malaysia, and Indonesia.
87GF Score
Get the complete analysis for TPE:4104
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4104 has been successfully added to your 
